Molecules 2011, 16(5), 3896-3907; doi:10.3390/molecules16053896
Article

Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats

1,†, 2,†, 1,* email and 3,* email
Received: 12 January 2011; in revised form: 28 April 2011 / Accepted: 4 May 2011 / Published: 10 May 2011
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The prevalence of metabolic syndrome has increased in modern society and the condition is proving to be a common precursor of cardiovascular disease. The aim of the present study was to investigate whether astragaloside IV, a major active constituent of Astragalus membranaceus (Fisch) Bge., is able to prevent the development of hypertension and endothelial dysfunction in fructose-fed rats. Rats were fed with 10% fructose in their drinking water for 8 weeks. From the beginning of week 5, two groups of fructose-fed rats were treated with 0.5 or 2 mg/kg, i.p., astragaloside IV. Another group of fructose-fed rats, injected with the same volume of vehicle (dimethylsulfoxide, DMSO) from week 5, served as the control group. At the end of the treatment period, blood pressure, blood glucose, glucose tolerance, blood insulin and lipids were determined. In addition, in vitro experiments were conducted at the end of the eight week treatment period to evaluate endothelium-dependent aortic vasorelaxation, as well as myocardial and aortic tissue levels of nitrate and nitrite (NOx) and cGMP. Fructose-fed rats developed clustering signs of metabolic syndrome, such as increased bodyweight, mild hypertension, hyperinsulinaemia, hypertriglyceridaemia, impaired glucose tolerance and impaired endothelium-dependent vasorelaxation. Administration of astragaloside IV reduced blood pressure and triglyceride levels in fructose-fed rats and high dose of astragaloside IV also improved glucose tolerance and endothelium-dependent vasorelaxation. The astragaloside IV-induced improvement in vasorelaxation was associated with increased levels of aortic NOx and cGMP and was abrogated by blockade of nitric oxide synthase with NG-nitro-l-arginine methyl ester (l-NAME). On the basis of its favourable effects on lipid metabolism, endothelium-dependent vasorelaxation and the nitric oxide–cGMP-related pathway, astragaloside IV may be useful in ameliorating food-induced metabolic syndrome.
Keywords: astragaloside IV; fructose; hypertension; metabolic syndrome; vessel function
PDF Full-text Download PDF Full-Text [330 KB, Updated Version, uploaded 18 June 2014 19:38 CEST]
The original version is still available [183 KB, uploaded 18 June 2014 19:38 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Zhang, N.; Wang, X.-H.; Mao, S.-L.; Zhao, F. Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats. Molecules 2011, 16, 3896-3907.

AMA Style

Zhang N, Wang X-H, Mao S-L, Zhao F. Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats. Molecules. 2011; 16(5):3896-3907.

Chicago/Turabian Style

Zhang, Ning; Wang, Xu-Hui; Mao, Shi-Long; Zhao, Feng. 2011. "Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats." Molecules 16, no. 5: 3896-3907.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert